AINewsnow

SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool

SimBioSys announced on October 15, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance to TumorSight Risk, an artificial intelligence software device that analyzes breast MRI scans alongside pathology and clinical data to estimate a patient's risk of breast cancer recurrenc…

Read the full story at Unite.AI ↗

Timeline · 1 report

  1. 2026-10-15 12:46 · Unite.AI
    SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool

More stories

  1. Anthropic reports $16.8 billion Q3 revenue ahead of planned IPO — New York Times Technology
  2. Google launches its ‘universal' online shopping cart ahead of the holidays — The Verge AI
  3. NVIDIA RTX Spark Superchip Outperforms Apple M5 Max in AI Benchmarks — Engadget
  4. Amazon launches two new Bee AI devices with subscription plan — TechCrunch AI
  5. Bank of America hired 1,000 contractors to patch software flaws exposed by Anthropic's Mythos — CNBC Technology
  6. Weeks to Hours: SentinelOne on Cybersecurity Research with OpenAI — OpenAI YouTube
  7. Anthropic warns AI models may self-replicate on IoT devices within months — Financial Times AI
  8. Amazon Debuts Revamped Bee AI Wearables, $12-a-Month Subscription Plan — Bloomberg AI

Get the daily brief of stories like this at 6:30 every morning →